Cardiotoxicity of immune checkpoint inhibitors: A retrospective cohort study of 93,362 patients. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract does not include a ...
ST. LOUIS, Mo., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Wugen, Inc., a clinical-stage U.S. biotechnology company developing allogeneic, off-the-shelf cell therapies for the treatment of hematological ...
A study has demonstrated the potential of a novel ligand-based CAR T-cell therapy for targeting CD7-positive T-cell malignancies, including T-cell acute lymphoblastic leukemia (T-ALL) and T-cell ...
CTD402 is a universal CAR-T cell product targeting CD7 derived from healthy donors and intended for the treatment of T-ALL/LBL. It is genetically modified to avoid fratricide, graft-versus-host ...
A groundbreaking new treatment using genome-edited immune cells, developed by scientists at UCL (University College London) and Great Ormond Street Hospital (GOSH), has shown promising results in ...
WU-CART-007 is an investigational anti-CD7 CAR-T cell therapy for relapsed or refractory T-ALL/LBL, derived from healthy donor T cells to avoid malignant contamination. The phase 2 trial aims to ...
Outcomes of Ph-like B-lineage acute lymphoblastic leukemia in the era of novel therapies. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include a full ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results